Cargando…

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma

BACKGROUND: The present study aimed to investigate the impact of pre-sarcopenia on the prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: We enrolled 214 patients (71 ± 10 years old; 166 men and 48 women; 90% Child–Pugh grade A and 10% Child–Pugh grad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Hitomi, Kurosaki, Masayuki, Nakanishi, Hiroyuki, Takahashi, Yuka, Itakura, Jun, Tsuchiya, Kaoru, Yasui, Yutaka, Tamaki, Nobuharu, Takaura, Kenta, Komiyama, Yasuyuki, Higuchi, Mayu, Kubota, Youhei, Wang, Wann, Okada, Mao, Enomoto, Nobuyuki, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005492/ https://www.ncbi.nlm.nih.gov/pubmed/29912922 http://dx.doi.org/10.1371/journal.pone.0198812

Ejemplares similares

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy
por: Itakura, Jun, et al.
Publicado: (2015)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor
por: Osawa, Leona, et al.
Publicado: (2020)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms
por: Nakanishi, Hiroyuki, et al.
Publicado: (2016)

Irregular vascular pattern by contrast‐enhanced ultrasonography and high serum Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2016)

Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens
por: Tamaki, Nobuharu, et al.
Publicado: (2015)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy
por: Nakanishi, Hiroyuki, et al.
Publicado: (2020)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
por: Tamaki, Nobuharu, et al.
Publicado: (2020)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy
por: Takaura, Kenta, et al.
Publicado: (2022)

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
por: Kirino, Sakura, et al.
Publicado: (2020)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
por: Tsuchiya, Kaoru, et al.
Publicado: (2014)

Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population
por: Kirino, Sakura, et al.
Publicado: (2023)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Simple algorithm to narrow down the candidates to receive echocardiography in patients with chronic liver disease for suspected pulmonary hypertension
por: Yamashita, Koji, et al.
Publicado: (2022)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
por: Kaneko, Shun, et al.
Publicado: (2022)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Matsumoto, Hiroaki, et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
por: Ishido, Shun, et al.
Publicado: (2023)

Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma
por: Tamaki, Nobuharu, et al.
Publicado: (2017)

Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
por: Ishido, Shun, et al.
Publicado: (2023)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode
por: Koizumi, Yohei, et al.
Publicado: (2019)

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors
por: Izumi, Namiki, et al.
Publicado: (2010)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021)

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy
por: Tada, Toshifumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eru1ta4aotrbrkufjsgbp2omhs